rs72554665
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 8P and 1B. PP5_Very_StrongBP4
The NM_001360016.2(G6PD):c.1376G>T(p.Arg459Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000133 in 1,209,798 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 44 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.00025 ( 0 hom., 12 hem., cov: 23)
Exomes 𝑓: 0.00012 ( 0 hom. 32 hem. )
Consequence
G6PD
NM_001360016.2 missense
NM_001360016.2 missense
Scores
6
5
5
Clinical Significance
Conservation
PhyloP100: 3.69
Genes affected
G6PD (HGNC:4057): (glucose-6-phosphate dehydrogenase) This gene encodes glucose-6-phosphate dehydrogenase. This protein is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. G6PD is remarkable for its genetic diversity. Many variants of G6PD, mostly produced from missense mutations, have been described with wide ranging levels of enzyme activity and associated clinical symptoms. G6PD deficiency may cause neonatal jaundice, acute hemolysis, or severe chronic non-spherocytic hemolytic anemia. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PP5
Variant X-154532269-C-A is Pathogenic according to our data. Variant chrX-154532269-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 100058.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-154532269-C-A is described in Lovd as [Pathogenic]. Variant chrX-154532269-C-A is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.014364898). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
G6PD | NM_001360016.2 | c.1376G>T | p.Arg459Leu | missense_variant | 12/13 | ENST00000393562.10 | NP_001346945.1 | |
G6PD | NM_000402.4 | c.1466G>T | p.Arg489Leu | missense_variant | 12/13 | NP_000393.4 | ||
G6PD | NM_001042351.3 | c.1376G>T | p.Arg459Leu | missense_variant | 12/13 | NP_001035810.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
G6PD | ENST00000393562.10 | c.1376G>T | p.Arg459Leu | missense_variant | 12/13 | 1 | NM_001360016.2 | ENSP00000377192 | P4 |
Frequencies
GnomAD3 genomes AF: 0.000250 AC: 28AN: 112037Hom.: 0 Cov.: 23 AF XY: 0.000351 AC XY: 12AN XY: 34197
GnomAD3 genomes
AF:
AC:
28
AN:
112037
Hom.:
Cov.:
23
AF XY:
AC XY:
12
AN XY:
34197
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000813 AC: 148AN: 181938Hom.: 0 AF XY: 0.000584 AC XY: 39AN XY: 66812
GnomAD3 exomes
AF:
AC:
148
AN:
181938
Hom.:
AF XY:
AC XY:
39
AN XY:
66812
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000121 AC: 133AN: 1097708Hom.: 0 Cov.: 37 AF XY: 0.0000881 AC XY: 32AN XY: 363134
GnomAD4 exome
AF:
AC:
133
AN:
1097708
Hom.:
Cov.:
37
AF XY:
AC XY:
32
AN XY:
363134
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000250 AC: 28AN: 112090Hom.: 0 Cov.: 23 AF XY: 0.000350 AC XY: 12AN XY: 34260
GnomAD4 genome
AF:
AC:
28
AN:
112090
Hom.:
Cov.:
23
AF XY:
AC XY:
12
AN XY:
34260
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
70
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:15Other:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 21, 2023 | - - |
Pathogenic, criteria provided, single submitter | curation | Dunham Lab, University of Washington | Aug 12, 2022 | Variant found in unrelated hemizygotes with deficiency, some with anemia, jaundice, and kernicterus (PS4_M, PP4). Segregates with deficiency in multiple unrelated families (PP1). Decreased activity in red blood cells (1-52%) (PS3). Affects same amino acid as pathogenic 459R>P (ClinVar ID 10422) (PM5). Predicted to be disease causing by Mutation Taster and possibly damaging by PolyPhen (PP3). Below expected carrier frequency in gnomAD (PM2). Reported as pathogenic by multiple clinical testing groups (PP5). Post_P 0.9997 (odds of pathogenicity 28416, Prior_P 0.1). - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Dec 21, 2023 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with G6PD deficient haemolytic anaemia (favism) (MIM#300908). (I) 0109 - This gene is associated with X-linked recessive disease. Hemizygous males and homozygous females are commonly affected; however, some heterozygous female carriers can also be affected depending on X-inactivation. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to leucine. (I) 0253 - This variant is hemizygous. (I) 0305 - Variant is present in gnomAD >=0.01 and <0.03 for a recessive condition in the East Asian subpopulation (115 heterozygotes, 0 homozygotes, 43 hemizygotes). (I) 0309 - Multiple alternative amino acid changes at the same position have been observed in gnomAD (v2) (highest allele count: 1 heterozygote, 0 homozygotes, 1 hemizygote). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated glucose-6-phosphate dehydrogenase, C-terminal domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported many times as pathogenic, is referred to as the Canton variant, and is enriched in East Asian populations (ClinVar, PMID: 36315991). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Jun 06, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 459 of the G6PD protein (p.Arg459Leu). This variant is present in population databases (rs72554665, gnomAD 1.0%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with glucose-6-phosphate deficiency (PMID: 1562739, 2263506, 6714986, 8537082, 10643148, 11499668, 17726510, 20203002, 21446359, 25541721, 25775246, 26823837). It has also been observed to segregate with disease in related individuals. This variant is also known as Canton variant. ClinVar contains an entry for this variant (Variation ID: 100058). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on G6PD protein function. Experimental studies have shown that this missense change affects G6PD function (PMID: 16607506). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 02, 2021 | The G6PD c.1376G>T; p.Arg459Leu variant (rs72554665) is reported in the literature in the hemizygous, homozygous, and compound heterozygous states in individuals of East Asian descent affected with G6PD deficiency (Fu 2018, Stevens 1990, Tang 1992). Individuals carrying this variant have been shown to have G6PD enzymatic activity lower than levels found in the general Chinese population (Tang 1992) and this variant has been reported in 27.5% of positive newborn screens for G6PD deficiency in Guangxi, China (Fu 2018). The variant is reported in ClinVar (Variation ID: 100058), and it is found in the East Asian population with an overall allele frequency of 1.1% (157/14796 alleles with 42 hemizygotes) in the Genome Aggregation Database. The arginine at codon 459 is moderately conserved and is located in the dehydrogenase domain. Additionally, another missense variant at the same amino acid (p.Arg459Pro) has been observed in individuals with G6PD deficiency and is considered pathogenic (Calabro 1993). Based on available information, the p.Arg459Leu variant is considered to be pathogenic. References: Calabro V et al. Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency revealed by single-strand conformation and sequence analysis. Am J Hum Genet. 1993 Mar;52(3):527-36. Fu C et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. Sci Rep. 2018 Jan 16;8(1):833. Stevens D et al. G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg----Leu mutation. Nucleic Acids Res. 1990: 18(23):7190. Tang T et al. Diverse point mutations result in glucose-6-phosphate dehydrogenase (G6PD) polymorphism in Taiwan. Blood. 1992: 79(8):2135-40. - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 20, 2022 | PP4, PP5, PM5, PS3, PS4_moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 04, 2023 | In vitro functional studies indicate that R459L has a reduced catalytic efficiency of approximately 50% compared to wild type enzyme (Boonyuen et al., 2017); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 9891846, 34659341, 34746046, 2263506, 11499668, 14505231, 1953767, 29783823, 29339739, 11793482, 31374327, 34570182, 12215013, 34953813, 29251006, 35193651, 28376293, 35313968, 8571933, 28583873) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 09, 2015 | - - |
G6PD deficiency Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 05, 2019 | The G6PD c.1376G>T (p.Arg459Leu) missense variant, also described as G6PD Canton, is one of the most common glucose-6-phosphate dehydrogenase (G6PD) deficiency variants in certain Asian populations. Across a selection of the available literature, the p.Arg459Leu variant was observed in 116 G6PD deficiency cases, mostly in individuals of Chinese ancestry (Stevens et al. 1990; Tang et al. 1992; Cai et al. 2000; Deng et al. 2007; Phompradit et al. 2011; Yang et al. 2014). Control data are unavailable for the p.Arg459Leu variant, which is reported at a frequency of 0.01061 in the East Asian population of the Genome Aggregation Database including 42 hemizygotes in this population and 43 hemizygotes in the total population. Based on the evidence, the p.Arg459Leu variant is classified as pathogenic for glucose-6-phosphate dehydrogenase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NM_001042351.1:c.1376G>T in the G6PD gene has an allele frequency of 0.012 in East Asian subpopulation in the gnomAD database. The c.1376G>T (p.Arg459Leu) variant was observed in numerous G6PD deficiency cases, mostly in individuals of Chinese ancestry (PMID: 25440321; 22171972; 21874587). Experimental studies have shown that this missense change causes a significant reduction in enzyme activity and affinity for glucose-6-phosphate (PMID: 16607506). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. Pathogenic computational verdict because pathogenic predictions from DANN, DEOGEN2, FATHMM-MKL, MVP, MutationTaster and REVEL. ACMG/AMP Criteria applied: PS3; PS4; PP4; PP3. - |
Malaria, susceptibility to;C2720289:Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 18, 2022 | - - |
Malaria, susceptibility to Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 28, 2024 | - - |
G6PD-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 27, 2024 | The G6PD c.1376G>T variant is predicted to result in the amino acid substitution p.Arg459Leu. This variant, referred to as G6PD Canton, has previously been reported to causative for Glucose-6-Phosphate Dehydrogenase deficiency (Wang X et al 2021. PubMed ID: 34659341; Nuchprayoon I et al 2002. PubMed ID: 11793482; Stevens et al 1990. PubMed ID: 2263506; Yusoff NM et al 2002. PubMed ID: 12215013). This variant is interpreted as pathogenic. - |
G6PD AGRIGENTO Other:1
other, no assertion criteria provided | literature only | OMIM | May 24, 2017 | - - |
G6PD TAIWAN-HAKKA Other:1
other, no assertion criteria provided | literature only | OMIM | May 24, 2017 | - - |
G6PD GIFU Other:1
other, no assertion criteria provided | literature only | OMIM | May 24, 2017 | - - |
G6PD CANTON Other:1
other, no assertion criteria provided | literature only | OMIM | May 24, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;D;.
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
.;.;D;D
MetaRNN
Benign
T;T;T;T
MetaSVM
Pathogenic
D
MutationAssessor
Benign
L;L;L;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;.;D;D
REVEL
Pathogenic
Sift
Benign
.;.;T;T
Sift4G
Benign
T;.;T;T
Polyphen
P;P;P;.
Vest4
MVP
MPC
1.9
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at